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LONG-TERM URATE-LOWERINGtherapy in gout aims to pre-vent or reverse tissue urate crys-tal deposits and associated
symptoms and signs by maintaining
concentrations of uric acid (UA) be-
low the limit of solubility (6.8 mg/dL).1,2
However, it is common for UA levels
to exceed the recommended goal urate
range of less than 6.0 mg/dL2 during
oral urate-lowering therapy among the
5 to 6 million US patients with gout,3,4
a finding documented in a majority
of individuals treated with the most
frequently prescribed doses of allopu-
rinol (300 mg/d).5-8 Although dose
titration of available oral urate-
lowering agents can achieve target UA
in most patients, urate-lowering therapy
fails for perhaps 3% of patients9 be-
cause of refractoriness, contraindica-
tion, or intolerance. Without effective
urate lowering, many such patients
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Context Patients with chronic disabling gout refractory to conventional urate-
lowering therapy need timely treatment to control disease manifestations related to
tissue urate crystal deposition. Pegloticase, monomethoxypoly(ethylene glycol)–
conjugated mammalian recombinant uricase, was developed to fulfill this need.
Objective To assess the efficacy and tolerability of pegloticase in managing refrac-
tory chronic gout.
Design, Setting, and Patients Two replicate, randomized, double-blind, placebo-
controlled trials (C0405 and C0406) were conducted between June 2006 and Octo-
ber 2007 at 56 rheumatology practices in the United States, Canada, and Mexico in
patients with severe gout, allopurinol intolerance or refractoriness, and serum uric acid
concentration of 8.0 mg/dL or greater. A total of 225 patients participated: 109 in
trial C0405 and 116 in trial C0406.
Intervention Twelve biweekly intravenous infusions containing either pegloticase
8 mg at each infusion (biweekly treatment group), pegloticase alternating with pla-
cebo at successive infusions (monthly treatment group), or placebo (placebo group).
Main Outcome Measure Primary end point was plasma uric acid levels of less than
6.0 mg/dL in months 3 and 6.
Results In trial C0405 the primary end point was reached in 20 of 43 patients in the
biweekly group (47%; 95% CI, 31%-62%), 8 of 41 patients in the monthly group
(20%; 95% CI, 9%-35%), and in 0 patients treated with placebo (0/20; 95% CI, 0%-
17%; P .001 and .04 for comparisons between biweekly and monthly groups vs
placebo, respectively). Among patients treated with pegloticase in trial C0406, 16 of
42 in the biweekly group (38%; 95% CI, 24%-54%) and 21 of 43 in the monthly
group (49%; 95% CI, 33%-65%) achieved the primary end point; no placebo-
treated patients reached the primary end point (0/23; 95% CI, 0%-15%; P=.001 and
 .001, respectively). When data in the 2 trials were pooled, the primary end point
was achieved in 36 of 85 patients in the biweekly group (42%; 95% CI, 32%-54%),
29 of 84 patients in the monthly group (35%; 95% CI, 24%-46%), and 0 of 43 pa-
tients in the placebo group (0%; 95% CI, 0%-8%; P .001 for each comparison).
Seven deaths (4 in patients receiving pegloticase and 3 in the placebo group) oc-
curred between randomization and closure of the study database (February 15, 2008).
Conclusion Among patients with chronic gout, elevated serum uric acid level, and al-
lopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks
or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.
Trial Registration clinicaltrials.gov Identifier: NCT00325195
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progress to severe chronic gout char-
acterized by frequent arthritic flares,
chronic arthropathy, and enlarging to-
phi, often accompanied by deformity,
chronic pain, functional disability, and
impaired health-related quality of life
(QOL).10-12 High rates of cardiovascu-
lar (CV),13,14 metabolic, and renal co-
morbidities15 further complicate QOL
and management of individuals with
chronic gout.
In contrast to nonprimate mam-
mals, humans excrete UA rather than
the soluble metabolite allantoin as the
end product of purine metabolism be-
cause of mutational inactivation of the
urate oxidase (uricase) gene.16 Pegloti-
case, a recently approved9 mammalian
recombinant uricase conjugated to
monomethoxypoly(ethylene glycol),17-19
is an enzymatic alternative to conven-
tional urate-lowering agents. Intrave-
nously administered (IV) pegloticase re-
mains in the circulation where it rapidly
degrades urate.17,18 We hypothesize
that the resulting urate concentration
gradient draws extravascular urate into
the circulation for degradation and that
persistent reduction of extracellular
fluid urate concentration favors urate
crystal dissolution, with eventual nor-
malization of the body urate pool and
resolution of gout symptoms and signs.
Single- and multiple-dose studies of
pegloticase in patients with refractory
gout17,18,20 have established dose-
related UA reduction lasting several
weeks after each IV infusion. In a
3-month randomized open-label effi-
cacy and safety trial,20 profound and
sustained urate lowering occurred most
often when 8-mg pegloticase was in-
fused every 2 weeks. Here, we report
results of replicate, randomized, pla-
cebo-controlled, 6-month trials of the
urate-lowering and clinical efficacy and
tolerability of pegloticase in patients
with refractory gout.
METHODS
Patients were 18 years or older and met
the following criteria for refractory gout:
a baseline serum UA of 8.0 mg/dL or
greater (to convert to µmol/L, multi-
ply by 59.485) and at least 1 of the fol-
lowing: 3 or more self-reported gout
flares during the previous 18 months;
1 or more tophi; and gouty arthropa-
thy, defined clinically or radiographi-
cally as joint damage due to gout. Pa-
tients also had contraindication to
treatment with allopurinol or history of
failure to normalize UA despite 3 or
more months of treatment with the
maximum medically appropriate allo-
purinol dose (determined by the treat-
ing physician). Exclusion criteria were
glucose-6-phosphate dehydrogenase
deficiency (because of hemolysis/
methemoglobinemia associated with
administration of unmodified recom-
binant uricase), prior treatment with a
uricase-containing agent, pregnancy,
unstable angina, uncontrolled hyper-
tension (150/95 mm Hg) or cardiac
arrhythmia, uncompensated conges-
tive heart failure, renal dialysis, or solid
organ transplant.
This study received institutional
review board approval at each site.
Written informed consent and Health
Insurance Portability and Account-
ability Act assurances were completed
for each participant before enroll-
ment.
Two replicate, randomized, 6-month,
double-blind, placebo-controlled trials
(C0405 and C0406) were conducted at
56 rheumatology practices in the United
States, Canada, and Mexico between
June 2006 and October 2007. Starting
at week 1, patients received 2-hour IV
infusions of 250-mL 0.9% sodium chlo-
ride containing either pegloticase 8 mg
at each infusion (biweekly treatment
group), pegloticase 8 mg alternating
with placebo (every-4-week or monthly
treatment group), or placebo (placebo
group). As prespecified, the primary
end point was analyzed separately for
each trial, and safety and secondary end
points were analyzed using data pooled
from both trials. Randomization used
an automated interactive voice re-
sponse system and was stratified to en-
sure comparable numbers of patients
with tophi in each group.
Participants receivingurate-lowering
medication at screening underwent a
1-weekwashout.Gout flareprophylaxis
(colchicine, 0.6 mg once or twice daily,
or a nonsteroidal anti-inflammatory
drug) was initiated 1 week before first
infusion and continued throughout the
study. Prophylaxis against infusion-
related reactions (IRs) was given to
all patients before each infusion: oral
fexofenadine, 60 mg the evening before
and again before infusion; acetamino-
phen, 1000 mg; and IV hydrocortisone,
200 mg, immediately before infusion.
Efficacy End Points and Assessments
The primary efficacy end point was the
proportion of plasma UA responders in
each pegloticase treatment group vs the
placebo group. A responder was de-
fined as a patient with plasma UA less
than 6.0 mg/dL for 80% of the time or
longer during both months 3 and 6, the
periods extending, respectively, from
the week-9 infusion to just prior to the
week-13 infusion and from the week-21
infusion to the week-25 final study visit.
Plasma UA (measured in trichloroace-
tic acid–precipitated chilled plasma)
was chosen to study this end point in
order to avoid possible ex vivo serum
UA degradation by circulating pegloti-
case. Plasma UA was determined at
baseline, at 2 and 24 hours after initial
infusion, preceding each biweekly in-
fusion, and at 5 additional prespeci-
fied time points in both month 3 and
month 6: 2 hours, 1 day, and 7 days af-
ter the week-9 and week-21 infusions
and 2 hours and 7 days after the
week-11 and week-23 infusions.
Secondary end points included to-
phus resolution; reductions in the pro-
portion of patients with gout flare and
in the number of flares per patient dur-
ing months 1-3 and 4-6 of the trial; re-
ductions in tender joint count (TJC)
and swollen joint count (SJC); and pa-
tient-reported changes in pain, physi-
cal function, and QOL, measured, re-
spectively, by the Health Assessment
Questionnaire (HAQ) pain scale,21
HAQ–Disability Index (HAQ-DI),22-24
and 36-Item Short Form Health Sur-
vey (SF-36).25,26
Secondary end points were assessed
at baseline, at the week-13 and week-19
visits, and at the week-25 final visit. For
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tophus measurement, serial standard-
ized digital photographs of hands and
feet and up to 2 other sites with tophi
were obtained and compared by a
blinded central reader using computer-
assisted quantitative measurement and
key concepts of photographic assess-
ment of skin tumors by Response
Evaluation Criteria in Solid Tumors
(RECIST) software (MedStudio ver-
sion 4.4; Megasoft, Hyderabad, India).27
This validated method for evaluating
quantitative response of malignant skin
lesions to cancer treatments was ap-
plied based on analogy of tophaceous
mass lesions to malignant skin le-
sions. A tophus complete response (CR)
was defined as 100% reduction in the
measured area of at least 1 tophus (of
baseline diameter 5 mm) without
growth of any baseline tophus or ap-
pearance of any new tophus.
Gout flare (acute joint pain and
swelling requiring treatment) occur-
rence, duration, and severity were re-
ported by patients at time of occur-
rence and confirmed by investigator
interview. Each investigator assessed
SJC and TJC in 54 specified joints. Pa-
tients completed HAQ and SF-36 forms.
Values for SJC, TJC, and patient-
reported end points were imputed using
last observation carried forward28 for
participants not completing all infu-
sions and the week-25 final study visit.
Safety assessments included bi-
weekly physical examination and medi-
cal history and adverse event (AE) up-
dates and monthly complete blood
counts, serum chemistry, and urinaly-
sis. An AE occurring during infusion or
within 2 hours after was declared an IR
and prompted standardized assess-
ment: physical examination, electro-
cardiogram, and measurement of se-
rum tryptase (to detect significant mast
cell degranulation).
All participant files were reviewed in
a post hoc analysis by an indepen-
dent, blinded CV event adjudication
committee. Deaths and AEs consid-
ered possibly of CV type were as-
sessed using the Anti-Platelet Trial-
ists’ Collaboration (APTC) composite
of end points for the primary analy-
sis.29 Non-APTC serious CV events were
identified from a modified list30 of ad-
ditional serious CV AEs.
Serum samples for pegloticase-
antibody and pegloticase neutralization
assays were obtained before infusions at
weeks 1, 3, 5, 9, 13, 17, 21, and 25. Stan-
dard ELISA methodology was used to de-
tect IgM, IgG, and total pegloticase an-
tibody using pegloticase as capture
antigen and horseradish peroxidase–
conjugated secondary antibody.31,32 (See
eMethods for assay details, available at
http://www.jama.com.)
Statistical Analyses
A modified intent-to-treat population
(randomized patients who received at
least 1 infusion) was used for all effi-
cacy and safety determinations except
for deaths, which were tracked for all
patients from randomization to study
database closure and recorded as oc-
curring before, during, or after comple-
tion of the 25-week treatment period.
Each replicate trial was considered ad-
equately powered (80%) to demon-
strate a difference in responder rates of
35% vs 5% between each active treat-
ment group and the respective pla-
cebo treatment group (significance level
of P=.05 for each comparison).
Comparisons of baseline demograph-
ics and disease characteristics across
treatment groups were made using
analysis of variance for continuous para-
meters and the 2 test for categorical
parameters. The primary efficacy of pe-
gloticase in each trial was evaluated in
responder analyses, with patients who
withdrew before the week-25 final visit
designated nonresponders. The pro-
portion of responders in each pegloti-
case treatment group was compared
with that in the corresponding pla-
cebo group using the Fisher exact test.
Numbers of patients with a tophus CR
were compared between each pegloti-
case group and the placebo group using
the Fisher exact test. Flare frequencies
during months 1-3 and 4-6 were ana-
lyzed separately using the 2-sample t test,
comparing each pegloticase group with
placebo. Numbers of patients reporting
flares during these periods were com-
pared using the Fisher exact test. Com-
parisons of change from baseline for TJC
and SJC and in pain scores, HAQ-DI
scores, and SF-36 domains between each
pegloticase group and the placebo group
used the 2-sample t-test.
Two-sided analyses were per-
formed for all statistical tests. P values
less than .05 were considered signifi-
cant. All statistical analyses were per-
formed using Stata/SE version 11.2
(StataCorp, College Station, Texas).
RESULTS
A total of 225 participants (109 in trial
C0405 and 116 in trial C0406) were
randomized to the 3 study groups (pe-
gloticase biweekly or monthly or pla-
cebo) in a 2:2:1 ratio (FIGURE 1). All
urate-lowering, clinical efficacy, and tol-
erability analyses (except deaths) were
carried out on a modified intent-to-
treat population (n=212; 104 in trial
C0405 and 108 in trial C0406) com-
prising all randomized patients who re-
ceived at least 1 infusion. Baseline char-
acteristics were similar across the trials
and treatment groups; metabolic and
renal disorders were common and CV
comorbidities or risk factors were
present in more than 80% of study
participants (TABLE 1).
Primary Efficacy End Point
Plasma UA normalized within 24 hours
of the first infusion in all patients re-
ceiving pegloticase, but afterward, some
patients lost the urate-lowering re-
sponse whereas others maintained UA
less than 6.0 mg/dL throughout the trial.
The proportion of UA responders (de-
fined as a plasma UA 6.0 mg/dL for
80% of the time during months 3 and
6) in both pegloticase treatment groups
was significantly greater than for the
placebo group in the pooled analysis
(P .001 for both) (TABLE 2) and in the
individual trials. When analyzed sepa-
rately by dose, patients treated with bi-
weekly pegloticase experienced re-
sponse rates of 47% (20/43; 95% CI,
31%-62%) and 38% (16/42; 95% CI,
24%-54%) in the 2 trials. Patients
treated with monthly pegloticase re-
ported response rates of 20% (8/41; 95%
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CI, 9%-35%) and 49% (21/43; 95% CI,
33%-65%) in the 2 trials. Response rates
were 0% in both placebo groups (95%
CI, 0%-17% and 0%-15% in the 2 trials).
Serum UA was also measured at most
study time points, and the  coeffi-
cient, which provides a measure of
agreement between corresponding se-
rum and plasma UA values, was 0.74
(P .001), indicating near excellent
agreement between the 2 methods.
Mean plasma UA for responders was
substantially below 6.0 mg/dL for the
entire 6-month treatment period
(FIGURE 2). For nonresponders treated
with biweekly pegloticase, mean plasma
UA remained below 6.0 mg/dL through
week 10 but was above target levels at
all subsequent time points (Figure 2B).
These findings suggest that a loss of
urate-lowering efficacy manifested rela-
tively early following treatment initia-
tion. Among 74 patients treated with
pegloticase (33 of 85 in the biweekly
cohort and 41 of 84 in the monthly co-
hort) who lost urate-lowering efficacy
prior to trial completion or with-
drawal, 72 did so by month 4.
Secondary End Points
Forty percent of patients in the bi-
weekly pegloticase group and 21% in
the monthly group had a CR for 1 or
more tophi by the final visit compared
with 7% of patients receiving placebo
(P = .002 and P = .20, respectively)
(Table 2). Examples of tophus size re-
ductions in patients receiving pegloti-
case therapy are shown in eFigure 1 and
eFigure 2. During months 1-3, both the
incidence of gout flares (proportion of
patients suffering at least 1 flare) and
the number of flares per patient were
higher for pegloticase-treated patients
compared with the placebo group
(Table 2). However, with continued
treatment during months 4-6, signifi-
cant reductions were seen in the pro-
portion of patients with gout flare in
the biweekly treatment group vs the
placebo group (Table 2). Flares per pa-
tient were also numerically fewer dur-
ing this period with biweekly pegloti-
case treatment compared with placebo
treatment, but the difference was not
significant. There were also reduc-
tions in TJC and SJC in patients treated
with pegloticase compared with the re-
spective values in placebo recipients,
but only differences in TJC were sta-
tistically significant (Table 2).
Both pegloticase dosing groups re-
ported significant improvements in
Figure 1. Screening, Randomization, and Disposition During the Treatment Period for the
Study Populations of Trial C0405 and Trial C0406
134 Patients assessed for eligibility
116 Randomized
42 Included in primary analysis 43 Included in primary analysis 23 Included in primary analysis
46 Randomized to receive
pegloticase every 2 weeks
42 Received ≥1 dose (mlTT)
4 Did not receive pegloticase
46 Randomized to receive
pegloticase every 4 weeks
43 Received ≥1 dose (mlTT)
3 Did not receive pegloticase
24 Randomized to receive
placebo
23 Received ≥1 dose (mlTT)
1 Did not receive placebo
3-mo Assessment
33 Assessed
9 Withdrawn from trial
3-mo Assessment
37 Assessed
6 Withdrawn from trial
3-mo Assessment
23 Assessed
0 Withdrawn from trial
29 Completed study





11 Total withdrawn from trial
7 Adverse events
3 Withdrew consent
1 Lost to follow-up
20 Completed study
3 Total withdrawn from trial
1 Adverse event
1 Withdrew consent
1 Lost to follow-up
18 Excluded




128 Patients assessed for eligibility
109 Randomized
43 Included in primary analysis 41 Included in primary analysis 20 Included in primary analysis
44 Randomized to receive
pegloticase every 2 weeks
43 Received ≥1 dose (mlTT)
1 Did not receive pegloticase
43 Randomized to receive
pegloticase every 4 weeks
41 Received ≥1 dose (mlTT)
2 Did not receive pegloticase
22 Randomized to receive
placebo
20 Received ≥1 dose (mlTT)
2 Did not receive placebo
3-mo Assessment
38 Assessed
5 Withdrawn from trial
3-mo Assessment
35 Assessed
6 Withdrawn from trial
3-mo Assessment
20 Assessed
0 Withdrawn from trial
30 Completed study










1 Total withdrawn from trial
(lost to follow-up)
19 Excluded




The deaths occurred during the treatment period. Four additional patients died after randomization but out-
side of the treatment period: 1 patient randomized to the pegloticase biweekly treatment group and 3 patients
randomized to the placebo treatment group. mITT indicates modified intent-to-treat group.
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physical function and QOL compared
with placebo. Patient-reported pain
(visual analog scale) was significantly
reduced (Table 2) with biweekly peg-
loticase vs placebo. Treatment with bi-
weekly pegloticase was also associ-
ated with significant changes from
baseline in HAQ-DI scores21 and SF-36
Physical Component Summary scores
that met or exceeded the minimum
clinically important differences estab-
lished for the respective instrument in
inflammatory arthritides (Table 2).12,34-37
Adverse Events
One or more AEs occurred in more than
90% of participants in each treatment
group (TABLE 3). Serious AEs occurred
more frequently in patients treated with
biweekly (24%; 95% CI, 15%-34%) and
monthly pegloticase (23%; 95% CI, 14%-
33%) than in patients receiving placebo
(12%; 95% CI, 4%-25%). Gout flare was
the most common AE and was reported
in approximately 80% of patients across
the 3 pooled study groups.
Infusion-related reaction was the sec-
ond most common AE (occurring in
26%, 42%, and 5% of patients receiving
pegloticase biweekly, pegloticase
Table 1. Baseline Characteristics for Trial C0405 and Trial C0406 (Modified Intent-to-Treat Group)


















Age, mean (SD), y 58.2 (15) 55.1 (13) 57.2 (13) 54.3 (16) 53.9 (14) 53.8 (11)
Male sex, No. (%) 30 (69.8) 35 (85.4) 15 (75.0) 38 (91.5) 34 (79.1) 21 (91.3)
White race/ethnicity, No. (%)a 32 (74.4) 32 (78.0) 14 (70.0) 22 (52.4) 27 (62.8) 16 (69.6)
BMI, mean (SD)b 34.85 (8) 33.68 (8) 33.30 (6) 31 (6) 32 (8) 31 (8)
Gout characteristics
Duration, mean (SD), y 16 (14) 16 (11) 12 (9) 15 (11) 16 (9) 15 (10)
Acute flares in prior 18 mo, No. (quartiles)a 43 (4, 8, 10) 40 (4, 7.5, 12) 20 (4.5, 8,12) 41 (4, 6, 10) 43 (4, 7, 10) 23 (3, 5, 10)
Baseline tophi, No. (%) 29 (67.4) 31 (75.6) 14 (70.0) 33 (78.6) 33 (76.7) 15 (65.2)
Chronic synovitis or arthropathy, No. (%) 27 (62.8) 23 (56.1) 13 (65.0) 23 (54.8) 24 (55.8) 13 (56.5)
Serum uric acid, mean (SD), mg/dL 9.8 (1.6) 10.4 (1.8) 9.4 (1.6) 9.5 (1.7) 9.6 (1.7) 9.8 (1.6)
Comorbid conditions, No. (%)
1 of these CV conditions or risk factors 36 (84) 36 (88) 17 (85) 36 (86) 35 (81) 18 (78)
Hypertension 30 (70) 30 (73) 15 (75) 32 (76) 30 (70) 16 (70)
Dyslipidemia 24 (56) 21 (51) 13 (65) 18 (43) 20 (47) 7 (30)
Diabetes mellitus 13 (30) 8 (20) 5 (25) 11 (26) 10 (23) 3 (13)
Cardiac arrhythmia 10 (23) 5 (12) 6 (30) 10 (24) 4 (9) 1 (4)
Coronary artery disease 9 (21) 10 (24) 6 (30) 5 (12) 6 (14) 3 (13)
Cardiac failure/left ventricular dysfunction 8 (19) 4 (10) 4 (20) 4 (10) 4 (9) 2 (9)
Peripheral vascular disease 3 (7) 2 (5) 2 (10) 4 (10) 4 (9) 1 (4)
Cerebrovascular disease 3 (7) 2 (5) 0 1 (2) 1 (2) 1 (4)
Obesity (BMI 30) 29 (67) 27 (66) 14 (70) 21 (50) 28 (65) 10 (43)c
Chronic kidney diseased 12 (28) 13 (32) 6 (30) 14 (33) 12 (29)c 3 (13)
Sleep apnea syndrome 6 (14) 5 (12) 3 (15) 2 (5) 4 (9) 3 (13)
Venous thromboembolic disease 1 (2) 1 (2) 1 (5) 2 (5) 1 (2) 1 (4)
Abbreviations: BMI, body mass index; CV, cardiovascular.
SI conversion factor: To convert uric acid to µmol/L, multiply by 59.485.
aSelf-reported.
bCalculated as weight in kilograms divided by height in meters squared.
c Indicates 1 missing value.
dChronic kidney disease was defined as a creatinine clearance of less than 60 mL/min calculated with the Cockcroft-Gault equation.33
Table 2. End-Point Analyses for Primary and Secondary Outcomes (Pooled Modified Intent-to-Treat)a
Pegloticase Biweekly Pegloticase Monthly Placebo
Primary End Point
No. responders/No. treated (%) [95% CI]b
Pooled results 36/85 (42) [32 to 54] 29/84 (35) [24 to 46] 0/43 (0) [0 to 8]
P valuec .001 .001
Trial C0405 20/43 (47) [31 to 62] 8/41 (20) [9 to 35] 0/20 (0) [0 to 17]
P valuec .001 .04
Trial C0406 16/42 (38) [24 to 54] 21/43 (49) [33 to 65] 0/23 (0) [0 to 15]
P valuec .001 .001
(continued)
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Table 2. End-Point Analyses for Primary and Secondary Outcomes (Pooled Modified Intent-to-Treat)a (continued)
Pegloticase Biweekly Pegloticase Monthly Placebo
Secondary End Points
Resolution of 1 tophi, No. patients/No. evaluable
patients (%) [95% CI]
21/52 (40) [27 to 55] 11/52 (21) [11 to 35] 2/27 (7) [1 to 24]
P valuec .002 0.20
Flare incidence, No. patients/No. treated (%) [95% CI]
Months 1-3 64/85 (75) [65 to 84] 68/84 (81) [71 to 89] 23/43 (53) [38 to 69]
P valuec .02 .002
Months 4-6 28/69 (41) [29 to 53] 39/69 (57) [44 to 68] 29/43 (67) [51 to 81]
P valuec .007 .32
Flare frequency, No. flares per patient
Months 1-3, mean (SD) 2.3 (2.1) (n = 85) 2.7 (2.4) (n = 84) 1.2 (1.6) (n = 43)
[95% CI] (quartiles) [1.8 to 2.7] (1, 2, 4) [2.2 to 3.2] (1, 2, 4) [0.7 to 1.7] (0, 1, 2)
P valued .001 .001
Months 4-6, mean (SD) 0.8 (1.2) (n = 69) 1.5 (2.0) (n = 69) 1.3 (1.5) (n = 43)
[95% CI] (quartiles) [0.5 to 1.1] (0, 0, 1) [1.1 to 2.0] (0, 1, 3) [0.8 to 1.7] (0, 1, 2)
P valued .06 .45
Tender joints, No. per patient
Baseline mean (SD) 11.7 (13.0) (n = 84) 11.1 (13.5) (n = 83) 14.1 (14.8) (n = 43)
[95% CI] (quartiles) [8.9 to 14.5] (1, 7, 18.5) [8.1 to 14.0] (1, 4, 16) [9.6 to 18.7] (3, 9, 21)
P valued .36 .26
Change at final visit, mean (SD) −7.4 (11.9) (n = 78) −6.1 (10.6) (n = 77) −1.2 (12.3) (n = 43)
[95% CI] (quartiles) [−10.1 to −4.7] (−9, −3, 0) [−8.6 to −3.7] (−11, −3, 0) [−5.0 to −2.6] (−6, −1, 3)
P valued .01 .03
Swollen joints, No. per patient
Baseline, mean (SD) 8.9 (11.1) (n = 84) 10.1 (10.0) (n = 83) 13.2 (13.7) (n = 43)
[95% CI] (quartiles) [6.5 to 11.3] (1, 5, 10) [7.9 to 12.2] (2, 7, 15) [8.9 to 17.4] (2, 11, 18)
P valued .08 .19
Change at final visit, mean (SD) −5.5 (10.5) (n = 78) −5.1 (7.8) (n = 77) −2.6 (11.6) (n = 43)
[95% CI] (quartiles) [−7.9 to −3.2] (−8, −2.5, 0) [−6.9 to −3.3] (−7, −3, 0) [−6.2 to 1.0] (−6, −2, 0)
P valued .18 .22
HAQ-DI scoree
Baseline, mean (SD) 1.10 (0.86) (n = 83) 1.21 (0.86) (n = 84) 1.24 (0.95) (n = 43)
[95% CI] (quartiles) [0.92 to 1.29] (0.25, 1.00, 1.88) [1.02 to 1.39] (0.38, 1.12, 2.00) [0.94 to 1.53] (0.25, 1.12, 2.12)
P valued .43 .86
Change at final visit, mean (SD) (MCID 0.22) −0.22 (0.64) (n = 77) −0.20 (0.55) (n = 78) 0.02 (0.41) (n = 43)
[95% CI] (quartiles) [−0.37 to−0.08] (−0.50,−0.12,0.00) [−0.32 to−0.07] (−0.50,−0.06,0.00) [−0.11 to 0.15] (−0.12, 0.00, 0.25)
P valued .01 .01
HAQ pain scoref
Baseline, mean (SD) 44.2 (27.7) (n = 84) 45.1 (27.0) (n = 84) 53.9 (28.1) (n = 43)
[95% CI] (quartiles) [38.2 to 50.2] (21.5, 45.0, 68.0) [39.2 to 50.9] (21.0, 50.0, 63.5) [45.3 to 62.5] (29.0, 58.0, 75.0)
P valued .07 .09
Change at final visit, mean (SD) (MCID 10) −11.4 (33.8) (n = 78) −6.9 (27.0) (n = 78) 1.4 (30.0) (n = 43)
[95% CI] (quartiles) [−19.1 to −3.8] (−37.0, −8.0, 8.0) [−13.0 to −0.8] (−22.0, −2.5, 8.0) [−7.9 to 10.6] (−15.0, −1.0, 14.0)
P valued .03 .14
SF-36 Physical Component Summary scoreg
Baseline, mean (SD) 35.2 (10.9) (n = 83) 33.3 (9.8) (n = 84) 31.0 (11.1) (n = 43)
[95% CI] (quartiles) [32.8 to 37.5] (27.1, 33.3, 43.1) [31.1 to 35.4] (26.2, 33.1, 40.3) [27.6 to 34.4] (22.0, 27.8, 39.3)
P valued .05 .26
Change at final visit, mean (SD) (MCID 2.5) 4.4 (9.4) (n = 77) 4.9 (8.5) (n = 77) −0.3 (9.0) (n = 43)
[95% CI] (quartiles) [2.3 to 6.5] (−1.2, 3.1, 9.9) [3.0 to 6.9] (−0.1, 3.0, 10.5) [−3.1 to 2.5] (−4.0, −0.1, 3.1)
P valued .01 .002
Abbreviations: CI, confidence interval; HAQ, Health Assessment Questionnaire; HAQ-DI, HAQ–Disability Index; MCID, minimal clinically important difference; SF-36, 36-Item Short Form
Health Survey.
SI conversion factor: To convert uric acid to µmol/L, multiply by 59.485.
aPooled data from the 2 replicate studies. As prespecified, the primary end point was analyzed separately for each study; key secondary end points were analyzed for the pooled popu-
lation. Comparisons are between each treatment group and the corresponding individual or pooled placebo group. Numbers of patients for the analyses of tender joints, HAQ-DI, HAQ
pain score, and SF-36 physical component summary score are for patients who had baseline and at least 1 follow-up assessment, with the final visit for each patient included (last
observation carried forward).28
bPlasma uric acid values 6.0 mg/dL during 80% of the time during months 3 and 6.
cFisher exact test.
dTwo-sample t test (unequal variances).
eTwenty questions regarding various physical activities including activities of daily living are scored from 0, “no difficulty,” to 3, “unable to do without help or use of aids.” The individual
scores are averaged, with weighting for use of help, to obtain a final score between 0 and 3.34-36
fPain was scored from 0 to 100 mm on the HAQ visual analog scale.
gSF-36 evaluates 12 domains spanning physical and mental components.12,36,37
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monthly, and placebo, respectively) and
was also the most common reason for
study discontinuation among pegloti-
case-treated patients (10% for bi-
weekly; 13% for monthly). Serious IRs
occurred in 5% (pegloticase biweekly)
and 8% (pegloticase monthly) of pa-
tients. Resolution of all IRs began within
minutes of slowing or discontinuing the
infusion or initiating supportive treat-
ment (which included epinephrine in 1
patient). All IRs resolved completely. Se-
rum tryptase levels were increased in 12
of 108 IRs (10.2%), including 3 in-
stances of IR classified as serious. In a ret-
rospective analysis of IRs, 5 patients ex-
perienced IRs with signs and symptoms
that met the criteria for anaphylaxis from
the National Institute of Allergy and In-
fectious Disease/Food Allergy and Ana-
phylaxis Network.38 These included 2 pa-
tients each in the pegloticase biweekly
and pegloticase monthly cohort and a
fifth patient who experienced these clini-
cal features during the first infusion of
the biweekly regimen. All of these reac-
tions were judged as mild to moderate
in severity by the investigator; 2 pa-
tients were treated with antihistamines
and 1 with glucocorticoids. Serum trypt-
ase activity was elevated in 1 of 5 pa-
tients. All signs and symptoms resolved
completely in these 5 patients, and 3 of
5 continued in the trial.
Seven deaths (4 among patients as-
signed pegloticase and 3 in the placebo
group) occurred between randomiza-
tion and closure of the study database
(February 15, 2008). One patient ran-
domized to placebo died before the first
infusion; 3 patients, each assigned peg-
loticase, died during the 6-month treat-
ment period; and 3 patients (1 assigned
pegloticase and 2 placebo) died after
completing the treatment period
(Figure 1 and Table 3). Two deaths
during the treatment period were
attributed to CV AEs (cardiac arrest in
a 61-year-old man and arrhythmia in a
69-year-old man) in the biweekly peg-
loticase group. The third treatment pe-
riod death resulted from renal failure in
a 64-year-old man (monthly pegloti-
case) who withdrew from dialysis initi-
ated during a hospitalization. Other
non-CV related deaths occurring out-
side the treatment period included meth-
icillin-resistantStaphylococcusaureus sep-
sis in an 89-year-old man 12 weeks after
completing biweekly pegloticase treat-
ment; recurrent chronic lymphocytic leu-
kemia in an 80-year-old man receiving
placebo; and multiorgan failure in an 85-
year-old woman who was randomized to
placebo but died before infusion. One
death (cause indeterminate becauseof in-
sufficient information) occurred 4
months after study withdrawal in a
67-year-old placebo-treated man with
a history of congestive heart failure and
insulin-dependent diabetes mellitus.
Three APTC events were identified
by the adjudication committee: 2 CV













































































Month 3 Month 6
Monthly treatment group
Month 3 Month 6
Responders are patients in each treatment group sustaining plasma uric acid (UA) levels of less than 6.0 mg/dL
for 80% of the time in months 3 and 6 of the trial; nonresponders are patients in each group not sustaining UA
levels less than 6.0 mg/dL throughout the trial. All patients treated with placebo were nonresponders. Plasma
UA levels were determined at baseline; at 2 and 24 hours after the first infusion (which occurred at week 1);
before each biweekly infusion; and at 2 hours, 1 day, and 7 days after the week-9 and week-21 infusions.
Achievement or failure to achieve responder status was determined for each patient from a plot made from
the multiple UA determinations during months 3 and 6. Dotted line indicates treatment response threshold;
error bars indicate 95% confidence intervals.
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deaths in patients treated with bi-
weekly pegloticase (described in pre-
ceding paragraph) and 1 nonfatal myo-
cardial infarction in a pegloticase
monthly patient. All APTC events oc-
curred in patients with 4 or more CV
risk factors at baseline. Serious non-
APTC events occurred in 2 patients in
the biweekly group (2.3%; 95% CI,
0.3%-8.2%), 6 patients in the monthly
group (7.1%; 95% CI, 2.7%-14.9%), and
0 patients in the placebo group (95%
CI, 0%-8.2%). All non-APTC events oc-
curred in patients with prior histories
of CV disease but were not clustered by
event category or duration of pegloti-
case treatment.
Immunogenicity
Antibodies to pegloticase appeared early
in treatment and were detected in 134
of 150 patients treated with pegloti-
case (89%; 95% CI, 83%-94%). Peg-
loticase antibody was of IgM and IgG
isotypes and, with the exception of an-
tibody from 1 patient, did not neutral-
ize pegloticase activity in vitro.
Only 1 of 52 (2%; 95% CI, 0.0%-
10%) pegloticase-treated patients with
pegloticase antibody exceeding a titer
of 1:2430 at any time maintained a
urate-lowering response to therapy. In
contrast, 52 of 82 (63%; 95% CI, 52%-
74%) pegloticase-treated patients who
remained in the study for 2 months or
longer and never had pegloticase-
antibody titer greater than 1:2430 main-
tained their urate-lowering responses.
A post hoc analysis comparing re-
sponse rates in patients with and
without antibody titers exceeding
1:2430 revealed a significant differ-
ence (P .001).
Antibody titers against pegloticase
may also have been associated with the
incidence of IRs in the 2 trials. Infusion-
related reactions were reported in 31 of
52 patients (60%; 95% CI, 45%-72%)
with pegloticase-antibody titers greater
than 1:2430 at any time during the trial,
compared with 16 of 84 patients (19%;
95% CI, 11%-29%) in whom pegloti-
case-antibody titer never exceeded
1:2430 (P .001). Although IRs were
more common in patients with high ti-
ters of pegloticase antibody at some
point during treatment, antibody ti-
ters at the time of occurrence of the first
IR did not reliably predict IR. In con-
trast and importantly, a post hoc analy-
sis found that loss of urate-lowering ef-
ficacy (plasma UA 6.0 mg/dL)
preceded the first IR in 91% (20/22 re-
ceiving biweekly pegloticase; 95% CI,
71%-99%) and 71% (24/34 receiving
monthly pegloticase; 95% CI, 53%-
85%) of patients with IRs.
COMMENT
These parallel, 6-month, placebo-
controlled trials of pegloticase treat-
ment have documented sustained UA
reductions and significant clinical im-
provements in a substantial propor-
tion of patients with chronic gout and
refractoriness to, or intolerance of, con-
ventional urate-lowering therapy. The
Table 3. Number of Pooled Replicate Modified Intent-to-Treat Group Patients Experiencing
Treatment-Emergent Adverse Eventsa
Event









Any AE 80 (94) 84 (100) 41 (95)
Any serious AE 20 (24) 19 (23) 5 (12)
Deathb 2 (2) 1 (1) 0
Discontinuation owing to AE 15 (18) 16 (19) 1 (2)
Most commonly reportedc
Gout flare 65 (76) 71 (85) 35 (81)
Infusion reaction 22 (26) 35 (42) 2 (5)
Headache 8 (9) 9 (11) 4 (9)
Nausea 10 (12) 6 (7) 1 (2)
Back pain 3 (4) 7 (8) 2 (5)
Nasopharyngitis 6 (7) 4 (5) 1 (2)
Dyspnea 4 (5) 5 (6) 2 (5)
Vomiting 4 (5) 5 (6) 1 (2)
Chest pain 5 (6) 4 (5) 1 (2)
Pruritus 3 (4) 5 (6) 0
Contusion 7 (8) 0 1 (2)
Pyrexia 2 (2) 5 (6) 1 (2)
Constipation 5 (6) 2 (2) 2 (5)
Blood pressure increased 0 6 (7) 0
Adjudicated CV events
APTC events 2 (2) 1 (1) 0
CV death 2 (2) 0 0
Nonfatal MI 0 1 (1)d 0
Non-APTC events 3 (2)e 6 (7) 0
CHF 2 (2) 1 (1) 0
Arrhythmia 1 (1) 1 (1) 0
DVT 0 1 (1) 0
TIA 0 1 (1) 0
Unstable angina 0 1 (1) 0
Coronary revascularization 0 1 (1) 0
Abbreviations: AE, adverse event; APTC, Anti-Platelet Trialists’ Collaboration; CHF, congestive heart failure; CV, cardio-
vascular; DVT, deep vein thrombosis; MI, myocardial infarction; TIA, transient ischemic attack.
aA treatment-emergent AE was defined as any event (except death) reported with a start date occurring on or after the
date of the first dose or any pre-existing condition that worsened on or after the first dose. Adverse events were cat-
egorized according to codes used in the Medical Dictionary for Regulatory Activities (MedDRA version 9.0) and listed in
descending order of total AEs for each item.
bDeaths recorded are those occurring during the 25-week treatment period. Additional deaths occurring in randomized
patients outside the treatment period are described in the “Results” section.
cThe most commonly reported AEs were defined as those occurring in 5% of patients in any treatment group and at
least 1% more frequently in patients treated with pegloticase compared with patients receiving placebo.
dOne patient had an APTC event (nonfatal myocardial infarction) and a non-APTC event (coronary revascularization), both
recorded here.
eOne patient had 2 non-APTC events (CHF and arrhythmia) and is not counted twice in the total percentage of affected
patients.
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significant disease-modifying benefits
of pegloticase given every 2 weeks (to-
phus resolution, reduced flare fre-
quency, reduction in TJC, and im-
proved patient-reported outcomes in
pain, physical function, and QOL) were
demonstrable within 6 months, a time
frame unique in randomized con-
trolled trials of urate-lowering agents.7,8
As documented here and previously
reported,11,12 chronic gout is associated
with decreased physical function and di-
minished QOL. Improvements in physi-
cal function and QOL scores exceeding
the minimal clinically important differ-
ence in pegloticase-treated patients,
coupled with deterioration in pain and
QOL in placebo-treated patients, pro-
vide evidence that chronic elevations in
UA are associated with significant func-
tional impairment as measured by sev-
eral criteria. This relationship has pre-
viously been difficult to distinguish from
functional impairment imparted by se-
rious comorbidities that typically char-
acterize gout patients, and therefore, the
ability of pegloticase to improve pa-
tient reported outcomes in this context
is noteworthy.
Infusion-related reactions, includ-
ing some cases fulfilling criteria for ana-
phylaxis, were the most common AEs
causing withdrawal from these trials.
Although all IRs resolved promptly and
without sequelae, minimizing the risk
for IRs is important for the safe ad-
ministration of pegloticase in clinical
practice.19 In our post hoc analysis, we
observed that most (79%) pegloticase-
treated patients experiencing IRs in
the course of development of high ti-
ters of pegloticase antibody did so only
after an associated loss of the urate-
lowering response to pegloticase. Since
all patients in this study received rou-
tine prophylaxis for IRs, including glu-
cocorticoids, the extent to which this
regimen may have mitigated the fre-
quency and severity of IRs is uncer-
tain. Nevertheless, it would seem pru-
dent to maintain IR prophylaxis in all
individuals receiving pegloticase
therapy.
A relatively small number of mecha-
nistically diverse albeit serious CV AEs
occurred during this study. Despite the
4-fold greater number of patients re-
ceiving pegloticase vs placebo, the el-
evated CV risk profile of this popula-
tion, and the absence of a compelling
mechanism connecting pegloticase with
CV AEs,39 the observed numerical im-
balance in these events underlines the
need for care in selecting patients for
pegloticase treatment. All patients who
had serious CV events had baseline CV
risk factors or previous events; thus,
measures to stabilize CV comorbidi-
ties prior to and during pegloticase
treatment would be appropriate.
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